Amyloidosis represents a heterogeneous group of life-threatening protein conformational disorders characterized by the extracellular deposition of insoluble, abnormally folded protein fibrils across diverse physiological tissues. When native soluble proteins undergo aberrant thermodynamic destabilization and self-assemble into highly organized cross-beta-sheet polymers, vital organ architectures become progressively disrupted, culminating in organ failure. Understanding the biological nuances, biochemical profiles, and phenotypic heterogeneity of this disease is fundamental to navigating its complex diagnostic landscapes and emerging targeted therapeutics.
Amyloidosis
1. Concise Definition
Amyloidosis is a complex systemic or localized disorder characterized by the extracellular accumulation of pathognomonic, fibrillar, insoluble proteinaceous deposits known as amyloid. These protein aggregates exhibit a distinctive cross-beta-sheet quaternary structure that resists conventional physiological proteolysis, subsequently displacing healthy parenchymal tissue and precipitating progressive multi-organ dysfunction.
At its biochemical foundation, the condition arises from a disruption in cellular proteostasis, wherein usually soluble precursor proteins undergo misfolding, self-aggregation, and fibrillogenesis. Depending on the biochemical identity of the aberrant precursor protein and its anatomical localization, amyloidosis can manifest as an isolated, organ-specific condition or as a rapidly fatal systemic syndrome primarily impairing cardiovascular, renal, neurological, and hepatic architecture.
2. Etymology & Linguistic Origin
The term amyloidosis derives linguistically from the Greek noun amylon (ἄμυλον), meaning “starch” or “fine meal,” combined with the suffix -eidos (εἶδος), signifying “form,” “resemblance,” or “appearance,” and the pathological suffix -osis (ωσις), denoting an abnormal state or morbid condition. Historically, the root adjective “amyloid” was adopted in botanical science by German botanist Matthias Schleiden in the 1830s to describe starch-like constituents found in plants.
In 1854, the German pathologist Rudolf Virchow introduced the term into medicine after observing that macroscopic cerebral and visceral deposits reacted with iodine and sulfuric acid in a manner indistinguishable from cellulose and starch. Although biochemical analyses subsequently demonstrated that these deposits were predominantly composed of proteinaceous filaments rather than carbohydrates, Virchow’s morphological nomenclature persisted, providing an enduring diagnostic terminology across modern pathology.
3. Pronunciation & Grammatical Form
Amyloidosis is pronounced phonetically as /ˌæm.ɪ.lɔɪˈdoʊ.sɪs/ in standard American English and /ˌæm.ɪ.lɔɪˈdəʊ.sɪs/ in British English. The primary lexical stress falls on the penultimate syllable (“-do-“).
Grammatically, the word operates as an uncountable clinical noun. Its plural form, though rarely encountered, is amyloidoses (/ˌæm.ɪ.lɔɪˈdoʊ.siːz/), which is utilized primarily when referring to distinct classification archetypes or diverse molecular subsets within the overarching spectrum of the disease. The corresponding adjectival form is amyloidotic or simply amyloid (e.g., amyloid deposits, amyloid cardiomyopathy, amyloid fibril).
4. Detailed Conceptual Explanation
Under physiological conditions, the human proteome maintains a finely calibrated balance between protein synthesis, folding, trafficking, and degradation—a coordinated equilibrium known as proteostasis. In patients with amyloidosis, this physiological quality control system fails. Precursor proteins that are intrinsically unstable, generated in non-physiological excess, or mutated at key residues undergo destabilizing conformational transitions. Instead of adopting or maintaining their native tertiary structures, these polypeptides expose hydrophobic core domains and align into rigid, non-branching antiparallel or parallel cross-beta sheets.
These pathogenic cross-beta sheets aggregate sequentially from transient oligomeric intermediates into protofilaments, which then intertwine to construct unbranched amyloid fibrils measuring approximately 7 to 12 nanometers in diameter. While traditional histological models posited that tissue injury was solely the result of mechanical displacement—in which excessive physical mass compressed microvascular networks and disrupted cellular architecture—contemporary molecular pathology recognizes a dual mechanism of cytotoxicity. Soluble pre-fibrillar oligomers exert direct cytotoxic effects by disrupting lipid bilayer integrity, inducing oxidative stress, perturbing intracellular calcium homeostasis, and triggering apoptotic cascades prior to overt fibril deposition.
Amyloid deposits are consistently non-homogeneous; besides the dominant precursor protein that defines the disease subtype, all amyloid fibrils incorporate non-fibrillar components. Universal non-fibrillar constituents include serum amyloid P component (SAP), a highly conserved pentraxin glycoprotein, alongside highly sulfated glycosaminoglycans (GAGs) and apolipoproteins. These auxiliary molecules act as a thermodynamic chaperone shield, stabilizing the fibril matrix against physiological extracellular proteases, scavenger receptor endocytosis, and macrophage phagocytosis, thereby perpetuating pathological tissue entrapment.
The anatomical distribution of amyloid determines its clinical trajectory. In localized amyloidosis, fibrillogenesis occurs adjacent to the site of protein synthesis, frequently manifesting in the upper respiratory tract, bladder, eyelid, or brain parenchyma (such as amyloid-beta in Alzheimer’s disease). Conversely, systemic amyloidosis involves precursor proteins circulating through the peripheral bloodstream, leading to generalized multi-organ infiltration. Organ systems vulnerable to functional decline include the myocardium, renal glomeruli, peripheral and autonomic nervous systems, soft tissues, and the gastrointestinal tract.
5. Historical Development
The macroscopic recognition of amyloid deposits precedes its contemporary biochemical characterization by centuries. In 1639, Nicolaus Fontanus documented an early macroscopic description of an abnormally enlarged, firm liver with peculiar waxy changes. By 1842, Austrian pathologist Carl von Rokitansky detailed a systemic condition he classified as “lardaceous disease” (Speckkrankheit), noting that the livers, spleens, and kidneys of chronically afflicted patients exhibited a waxy, translucent, bacon-like appearance on post-mortem dissection.
A critical shift occurred in 1854 when Rudolf Virchow demonstrated that the lardaceous substance stained deep brown upon exposure to iodine, turning dark blue-violet after the addition of dilute sulfuric acid. Virchow mistakenly deduced that the deposits were homologous to vegetable starch, christening the phenomenon “amyloid.” In 1859, chemists Friedrich Kekulé and Carl Schmidt demonstrated through elemental analysis that the deposits contained excessive nitrogen concentrations consistent with proteins, conclusively disproving Virchow’s carbohydrate hypothesis, though the morphological label remained.
The early twentieth century introduced optical histopathology breakthroughs. In 1922, Paul Bennhold discovered that Congo red dye bound specifically to amyloid deposits. Shortly thereafter, in 1927, Belgian researchers Pol Divry and Marcel Florkin discovered that Congo red-stained amyloid exhibited a distinctive “apple-green” birefringence when illuminated by cross-polarized light, establishing what remains the gold standard histological hallmark of amyloid fibrils. In 1959, Alan S. Cohen and Evan Calkins utilized transmission electron microscopy to prove that all forms of amyloid, irrespective of biological source, shared an identical, unbranched, fibrillar ultrastructure.
Molecular resolution advanced precipitously in the 1970s through the pioneer work of George Glenner at the National Institutes of Health. Glenner successfully isolated and sequenced the primary amino acid structure of amyloid fibrils from a patient with primary amyloidosis, revealing that they were composed of immunoglobulin light chain fragments. This proved that amyloidosis was not a single, monolithic disease entity, but rather a unified biophysical phenotype stemming from fundamentally distinct precursor proteins.
6. Theoretical Foundations
The pathophysiology of amyloidosis is grounded in the thermodynamic principles of protein folding landscapes. Under normal physiological circumstances, a linear polypeptide navigates a funnel-shaped free-energy landscape toward its lowest-energy, native conformational state, guided by molecular chaperones such as heat shock proteins. When thermal fluctuations, genetic mutations, post-translational modifications, or senescent stress disrupt this pathway, kinetic intermediates fall into alternate local energy minima, stabilizing as misfolded aggregates.
The predominant biophysical framework explaining amyloid fibril formation is the nucleated polymerization model. In this mechanistic paradigm, the formation of a critical oligomeric core—the “nucleus”—constitutes the rate-limiting, thermodynamically unfavorable phase known as the lag phase. Once this energetic barrier is breached, the addition of further monomeric precursors to the exposed ends of the nucleus becomes kinetically rapid, promoting exponential elongation. Furthermore, existing fibrils can undergo secondary nucleation, where the outer surfaces of formed fibrils catalyze the structural conversion of fresh soluble monomers, creating an autocatalytic feedback loop.
Another foundational model addresses the phenomenon of conformational proteotoxicity. Contemporary protein misfolding theory differentiates between the inert structural bulk of the mature, insoluble cross-beta fibril and the pathogenic potency of transient, pre-fibrillar oligomers. These oligomers expose unstable hydrophobic residues that insert directly into cell membranes, forming non-specific pores that compromise cell integrity. Understanding this paradigm shifts the therapeutic ambition from simply dissolving mature plaques to neutralizing pre-fibrillar species and silencing precursor protein production altogether.
7. Key Components, Types & Dimensions
The International Society of Amyloidosis (ISA) currently recognizes over 36 distinct fibril proteins implicated in human amyloid disease. The vast majority of clinical cases encountered in modern medical practice fall within four predominant systemic subtypes:
- AL Amyloidosis (Immunoglobulin Light Chain): Arising from an underlying clonal plasma cell dyscrasia or low-grade B-cell lymphoma, this variant features the excessive production of monoclonal immunoglobulin kappa (κ) or, more frequently, lambda (λ) light chains. These unstable light chains aggregate across tissues, predominantly inflicting severe restrictive cardiomyopathy, nephrotic-range proteinuria, autonomic neuropathy, and hepatomegaly.
- ATTR Amyloidosis (Transthyretin): Transthyretin (TTR) is a tetrameric transport protein synthesized by the liver that carries thyroxine and retinol-binding protein. ATTR occurs in two forms: ATTRwt (wild-type, historically termed senile systemic amyloidosis), driven by age-related conformational instability of normal TTR that primarily infiltrates the hearts of older adults; and ATTRv (variant/hereditary), induced by autosomal dominant missense mutations (such as Val30Met or Val122Ile) precipitating early-onset polyneuropathy, cardiomyopathy, or mixed clinical phenotypes.
- AA Amyloidosis (Reactive / Secondary): Driven by sustained, chronic inflammatory states (e.g., rheumatoid arthritis, familial Mediterranean fever, inflammatory bowel disease, osteomyelitis, or tuberculosis), this form involves the hypersecretion of Serum Amyloid A (SAA), an acute-phase apolipoprotein produced by hepatocytes. Chronic circulating elevations of SAA lead to proteolytic cleavage and fibril deposition, predominantly manifesting as renal dysfunction and end-stage kidney disease.
- ALECT2 Amyloidosis (Leukocyte Chemotactic Factor 2): A relatively newly recognized form common among individuals of Hispanic, Middle Eastern, and South Asian descent. It primarily targets the renal interstitium and liver, presenting with indolent renal insufficiency, typically sparing the myocardium.
- Aβ Amyloidosis (Amyloid Beta): A localized neurodegenerative subtype where cleavage fragments of the amyloid precursor protein (APP) accumulate as senile plaques within the neocortex in Alzheimer’s disease and infiltrate cerebral vessels in cerebral amyloid angiopathy (CAA).
- Aβ2M Amyloidosis (Beta-2 Microglobulin): Historically observed in patients undergoing long-term hemodialysis, as β2-microglobulin cannot be efficiently cleared by traditional dialyzer membranes, progressively accumulating within osteoarticular and synovial structures to cause carpal tunnel syndrome and destructive arthropathies.
8. Examples & Illustrative Cases
To grasp the profound clinical variability of amyloidosis, consider two illustrative presentations reflecting divergent biological origins:
Case Illustration 1: Systemic AL Amyloidosis
A 62-year-old female presents with progressive functional decline, unprovoked periorbital purpura (“raccoon eyes”), macroglossia (enlarged tongue with tooth indentations), and bilateral lower-extremity edema. Baseline echocardiography reveals concentric ventricular thickening with a characteristic “sparkling” myocardial texture, diastolic dysfunction, and an uncharacteristically preserved left ventricular ejection fraction. Laboratory evaluation reveals profound nephrotic proteinuria (6 g/24 hours), markedly elevated NT-proBNP, and an abnormal serum free light chain (FLC) ratio with a monoclonal lambda excess. A subcutaneous abdominal fat pad aspirate confirms amyloidosis via Congo red staining. This scenario exemplifies rapid-onset AL amyloidosis requiring urgent anti-plasma-cell chemotherapy to prevent fulminant cardiovascular collapse.
Case Illustration 2: Transthyretin Amyloid Cardiomyopathy (ATTRwt)
A 76-year-old male with a decade-long history of bilateral carpal tunnel syndrome release surgery and spinal stenosis presents with gradual exertional dyspnea, lightheadedness, and symptoms of heart failure with preserved ejection fraction (HFpEF). Electrocardiography shows low QRS voltage, directly discordant with marked ventricular hypertrophy visualized on echocardiography. Technetium-99m pyrophosphate (99mTc-PYP) bone scintigraphy reveals intense myocardial radiotracer uptake (Grade 3), surpassing rib uptake. In the absence of monoclonal light chains in the serum and urine, a diagnosis of wild-type ATTR cardiomyopathy is secured non-invasively, prompting initiation of targeted transthyretin-stabilizing pharmacotherapy.
9. Measurement & Assessment
The diagnostic verification of amyloidosis requires a multidisciplinary pathway that integrates histopathology, molecular classification, and high-resolution imaging modalities:
Histological confirmation remains an essential diagnostic tenet. The fundamental diagnostic test is Congo red staining performed on fixed tissue sections. When visualized under cross-polarized light microscopy, Congo red-stained amyloid exhibits pathognomonic “apple-green” birefringence. Biopsy selection ranges from minimally invasive screening sites—such as the subcutaneous abdominal fat pad or minor labial salivary glands—to affected target organs (endomyocardial, renal, or hepatic biopsies) when initial tissue screenings are non-diagnostic yet clinical suspicion remains high.
Once amyloid is confirmed histologically, accurate subtyping is imperative, as treating one variant with the therapeutics of another can be lethal. The current reference standard for amyloid typing is liquid chromatography-tandem mass spectrometry (LC-MS/MS) performed on microdissected, Congo red-positive tissue fragments. Mass spectrometry avoids the false positives and background cross-reactivity that can complicate conventional immunohistochemistry or immunofluorescence panels.
For cardiac amyloidosis, non-invasive imaging algorithms have transformed clinical practice. Cardiac Magnetic Resonance (CMR) imaging with late gadolinium enhancement (LGE) characteristically reveals diffuse subendocardial or transmural enhancement along with markedly expanded extracellular volume (ECV). Bone scintigraphy using bone-seeking radiotracers (such as 99mTc-PYP, 99mTc-DPD, or 99mTc-HMDP) selectively binds to ATTR myocardial deposits. A validated diagnostic algorithm allows for a definitive diagnosis of ATTR cardiomyopathy without a biopsy, provided there is intense cardiac uptake (Grade 2 or 3) and clonal plasma cell processes are strictly excluded via normal serum free light chain assays and serum/urine immunofixation electrophoresis.
10. Applications & Practical Significance
Recognizing and correctly characterizing amyloidosis holds life-or-death significance across multiple clinical specialties, including cardiology, nephrology, neurology, hematology, and oncology:
In clinical cardiology, wild-type ATTR is increasingly recognized as a hidden driver of heart failure with preserved ejection fraction and severe calcific aortic stenosis in the elderly. Identifying amyloidosis fundamentally alters clinical management. Conventional heart failure medications such as ACE inhibitors, angiotensin receptor blockers, and beta-blockers are frequently poorly tolerated or outright contraindicated due to profound hypotension and the heart’s dependence on fixed stroke volume and compensatory heart rate. Digoxin and calcium channel blockers are likewise avoided due to risk of increased toxicity from selective binding to amyloid fibrils.
In hematology and oncology, diagnosing AL amyloidosis necessitates rapid therapeutic intervention to eliminate the underlying malignant plasma cell clone. Treatment paradigms leverage novel systemic myeloma therapies, including the proteasome inhibitor bortezomib, cyclophosphamide, dexamethasone (CyBorD), and the anti-CD38 monoclonal antibody daratumumab, occasionally followed by high-dose melphalan conditioning and autologous stem cell transplantation.
In neurology and medical genetics, the diagnosis of hereditary ATTR variants prompts genetic counseling, predictive testing for asymptomatic family members, and the prompt deployment of innovative gene-silencing therapeutics that block pathogenic transthyretin production before irreversible axonal loss occurs.
11. Research & Empirical Evidence
The therapeutic landscape of amyloidosis has undergone a profound revolution over the past decade, shifting from empirical palliative interventions to precise, disease-modifying, mechanistically guided pharmacotherapies:
In ATTR cardiomyopathy, the landmark Phase III ATTR-ACT trial (Maurer et al., 2018) evaluated tafamidis, a small-molecule pharmacological chaperone that selectively binds to the thyroxine-binding sites of the native TTR tetramer. By thermodynamically stabilizing the tetramer, tafamidis inhibits its dissociation into amyloidogenic monomers. The trial demonstrated a significant 30% reduction in all-cause mortality and a 32% reduction in the rate of cardiovascular-related hospitalizations compared to placebo, establishing a benchmark in non-oncological amyloid therapy.
Simultaneously, genomic and RNA-targeted therapeutics have yielded profound success in hereditary ATTR amyloid polyneuropathy. The APOLLO trial (Adams et al., 2018) investigated patisiran, a lipid nanoparticle-formulated small interfering RNA (siRNA) that catalytically degrades hepatic TTR mRNA via the RNA interference pathway. Patisiran halted or reversed polyneuropathy progression and improved quality of life. Similar clinical success has been realized with inotersen, an antisense oligonucleotide (ASO), and next-generation second-wave siRNA modalities such as vutrisiran, each achieving greater than 80% to 90% sustained knock-down of circulating serum transthyretin levels.
In AL amyloidosis, the landmark ANDROMEDA trial (Kastritis et al., 2021) investigated the addition of subcutaneous daratumumab to the standard-of-care CyBorD regimen. The combination yielded unprecedented hematologic complete response rates and organ progression-free survival, firmly establishing daratumumab-CyBorD as the new frontline standard of care worldwide.
12. Cultural & Cross-Cultural Considerations
Amyloidosis exhibits marked epidemiological variations globally, influenced by ancestral genetics, regional prevalence of infectious diseases, and healthcare resource accessibility:
The genetic landscape of variant transthyretin amyloidosis (ATTRv) exhibits profound geographic and founder-effect clustering. The Val30Met (p.Val50Met) mutation displays distinct endemic foci in northern Portugal (Póvoa de Varzim), northern Sweden (Skellefteå), and select regions of Japan, typically manifesting as an early-onset sensorimotor and autonomic neuropathy. Conversely, the Val122Ile (p.Val142Ile) mutation is carried by an estimated 3% to 4% of individuals of African descent, particularly in the United States and the Caribbean, functioning as an underdiagnosed driver of late-onset cardiomyopathy and progressive heart failure.
Socioeconomic conditions and regional disease burdens substantially modulate secondary AA amyloidosis prevalence. In developing nations and historically underserved communities, AA amyloidosis remains prevalent, secondary to unchecked chronic infectious diseases like tuberculosis, untreated leprosy, and persistent osteomyelitis. In industrialized nations, improved infection control has rendered autoimmune conditions (such as rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease) the dominant drivers of AA, alongside autoinflammatory conditions like familial Mediterranean fever (FMF) common in populations of eastern Mediterranean descent.
13. Criticisms, Debates & Limitations
Despite significant scientific strides, the field of amyloidosis research faces several controversies and clinical challenges:
A major systemic critique centers on late diagnosis and misdiagnosis. Because amyloidosis mimics prevalent pathologies (e.g., hypertensive cardiomyopathy, diabetic neuropathy, or minimal change disease), patients routinely consult multiple specialists across an average diagnostic delay of two to three years before receiving a correct diagnosis. In AL amyloidosis, where the median untreated survival for advanced cardiac involvement is less than six months, such diagnostic delays are frequently fatal.
Considerable debate persists regarding the thermodynamic reversibility of established, mature amyloid plaques. While suppression of precursor protein supply (via clone eradication in AL or gene silencing in ATTR) halts new fibrillogenesis, the passive resorption of mature cross-beta fibrils by endogenous macrophage systems is notoriously slow and frequently incomplete. Clinical trials investigating therapeutic monoclonal antibodies designed to actively bind and clear tissue amyloid deposits (such as birtamimab, anselamimab, or PRX004) have yielded heterogeneous results, leaving plaque clearance a contested clinical milestone.
Additionally, the economic sustainability of novel therapies has sparked sharp criticism. First-generation TTR stabilizers and gene-silencing platforms carry annual costs running into hundreds of thousands of dollars per patient. This pricing model creates steep disparities in healthcare equity, restricting access primarily to well-insured patients in developed countries while remaining completely inaccessible across low- and middle-income regions.
14. Related Terms & Distinctions
Understanding amyloidosis requires delineating it from several related terms and pathological phenotypes:
- Amyloidosis vs. Amyloid: Amyloid refers strictly to the structural, insoluble, beta-sheet-rich proteinaceous substance itself. Amyloidosis defines the broader pathological state, clinical syndrome, or disease process triggered by the accumulation of that substance within biological tissues.
- Amyloidosis vs. Light Chain Deposition Disease (LCDD): Both are plasma cell dyscrasias involving monoclonal immunoglobulins. However, LCDD features non-fibrillar, granular light chain deposits that do not form beta-sheet fibrils, do not demonstrate Congo red birefringence, and do not show the characteristic fibrillar arrays on electron microscopy.
- Systemic Amyloidosis vs. Localized Amyloidosis: Systemic amyloidosis involves an intravascular precursor protein that circulates freely and settles into distant organs. Localized amyloidosis represents an organ-confined process (such as amyloid deposition in vocal cords, isolated cutaneous nodules, or cerebral Aβ deposits) where the precursor is synthesized, aggregated, and retained entirely within the immediate local tissue environment, carrying a much better overall prognosis.
- Amyloid Plaque vs. Neurofibrillary Tangle: In Alzheimer’s disease, amyloid plaques refer to extracellular deposits of amyloid-beta protein. Neurofibrillary tangles, by contrast, consist of intracellular aggregates of hyperphosphorylated tau protein, which adopt a paired helical filament configuration inside dying neurons.
15. Summary / Key Takeaways
Amyloidosis is not a single disease, but a diverse family of protein conformational disorders characterized by the extracellular deposition of insoluble, cross-beta-sheet fibrils. When native proteins misfold, they create toxic oligomeric precursors that assemble into durable fibrils, disrupting tissue architecture and driving progressive organ failure. Primary systemic archetypes include light-chain amyloidosis (AL), transthyretin amyloidosis (ATTR, in both wild-type and hereditary forms), and reactive amyloid A (AA) amyloidosis.
Historically recognized by Rokitansky and Virchow as a starch-like material, amyloid is histologically identified by Congo red staining displaying an apple-green birefringence under cross-polarized light. Accurate subtyping through mass spectrometry (LC-MS/MS) and non-invasive methods (such as bone scintigraphy for cardiac ATTR) is vital to ensure appropriate treatment selection. Therapeutic interventions have advanced from palliative care to modern precision pharmacotherapy, incorporating plasma-cell clone suppression, kinetic tetramer stabilizers like tafamidis, and targeted mRNA-silencing platforms like siRNA and antisense oligonucleotides.
Ultimately, amyloidosis serves as a prime example of the clinical impact of biophysical instability, highlighting how small changes in protein folding can trigger systemic, multi-organ disease.
References
- Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C. C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., Lin, K. P., Vita, G., Attarian, S., Planté-Bordeneuve, V., Mezei, M. M., Campistol, J. M., Buades, J., Brannagan, T. H., Kim, B. J., … Suhr, O. B. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine, 379(1), 11–21. https://doi.org/10.1056/NEJMoa1716153
- Glenner, G. G. (1980). Amyloid deposits and amyloidosis: The β-fibrilloses. New England Journal of Medicine, 302(23), 1283–1292. https://doi.org/10.1056/NEJM198006053022305
- Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., Lu, J., Schönland, S., Gatt, M. E., Suzuki, K., Kim, K., Cibeira, M. T., Beksac, M., Libby, E., Valent, J., … Comenzo, R. L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. New England Journal of Medicine, 385(1), 46–58. https://doi.org/10.1056/NEJMoa2028631
- Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, M., Judge, D. P., Barsdorf, A. I., Huber, P., Patterson, T. A., Riley, S., Schumacher, J., … Rapezzi, C. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 379(11), 1007–1016. https://doi.org/10.1056/NEJMoa1805689
- Merlini, G., & Bellotti, V. (2003). Molecular mechanisms of amyloidosis. New England Journal of Medicine, 349(6), 583–596. https://doi.org/10.1056/NEJMra023144